TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21288804

Group type: EXPERIMENTAL
Intervention: Booster dose of IXIARO (IC51) administered 15 months after primary immunization.
Number of subjects: 198
Study: 19595518

Group type: EXPERIMENTAL
Intervention: Topiramate (up to 300 mg/day)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Naltrexone (50 mg/day)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study: 16458598

Group type: EXPERIMENTAL
Intervention: 24-h nicotine patch
Number of subjects: 20

Group type: COMPARATOR
Intervention: 16-h nicotine patch
Number of subjects: 20
Study: 12549956

Group type: EXPERIMENTAL
Intervention: Desloratadine (once-daily treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10965735

Group type: EXPERIMENTAL
Intervention: 25 mg oral dexketoprofen
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 50 mg oral ketoprofen
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 500 mg oral paracetamol
Number of subjects: 45

Group type: COMPARATOR
Intervention: Rescue tramadol
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Overall pain relief
Number of subjects: 45
Study: 9005368

Group type: EXPERIMENTAL
Intervention: Ipriflavone 600 mg/day per os
Number of subjects: 30

Group type: COMPARATOR
Intervention: Leuprolide acetate 3.75 mg monthly intramuscularly
Number of subjects: 30
Study: 1453211

Group type: EXPERIMENTAL
Intervention: 32-mg single dose of ondansetron
Number of subjects: 699

Group type: COMPARATOR
Intervention: 8-mg single dose of ondansetron
Number of subjects: 699

Group type: COMPARATOR
Intervention: 0.15 mg/kg times three doses of ondansetron
Number of subjects: 699
Study: 3893704

Group type: EXPERIMENTAL
Intervention: Pirprofen (400 mg/4 ml)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Noramidopyrine (1 gm/2 ml)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pirprofen
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both NSAIDs
Number of subjects: 34
Study: 31357916

Group type: EXPERIMENTAL
Intervention: BA+exercise
Number of subjects: 31

Group type: COMPARATOR
Intervention: BA+stretching
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups (BA+exercise and BA+stretching)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: More exercise engagement
Number of subjects: 31
Study: 28386808

Group type: EXPERIMENTAL
Intervention: The Mindfulness‐Enhanced Strengthening Families Program 10‐14 (MSFP 10‐14)
Number of subjects: 515

Group type: COMPARATOR
Intervention: The Strengthening Families Program: For Parents and Youth 10‐14 (SFP 10‐14)
Number of subjects: 515
Study: 26332107

Group type: EXPERIMENTAL
Intervention: ECG‐gated 64‐slice multidetector computed tomography (MDCT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ECG‐gated 128‐DSCT
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nongated 128‐DSCT
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (ECG‐gated 64‐slice MDCT)
Number of subjects: 60
Study: 24417710

Group type: EXPERIMENTAL
Intervention: Algorithm of three physician billing codes (separated by at least 30 days) in 2 years or one hospitalization
Number of subjects: 7500
Study: 22237311

Group type: EXPERIMENTAL
Intervention: SB-649868 10 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: SB-649868 30 mg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Zolpidem 10 mg
Number of subjects: 51
Study: 20072058

Group type: EXPERIMENTAL
Intervention: Active stretching (12 x 15 seconds)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Active stretching (6 x 30 seconds)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Active stretching (4 x 45 seconds)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no stretching)
Number of subjects: 150
Study: 18046055

Group type: EXPERIMENTAL
Intervention: Milk (mixed protein‐carbohydrate)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Carbohydrate (CHO)
Number of subjects: 5
Study: 16124965

Group type: EXPERIMENTAL
Intervention: 4 consecutive days of activity sampling
Number of subjects: 131

Group type: COMPARATOR
Intervention: 7 or more days of activity sampling
Number of subjects: 131
Study: 12183720

Group type: EXPERIMENTAL
Intervention: TUDCA (30 mg/kg/day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (untreated/placebo)
Number of subjects: 52
Study: 10357350

Group type: EXPERIMENTAL
Intervention: Combitube (CT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Endotracheal intubation (ET)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 75
Study: 8543491

Group type: EXPERIMENTAL
Intervention: Meropenem 500 mg intravenously every 8 h
Number of subjects: 153

Group type: COMPARATOR
Intervention: Ceftazidime 250-1000 mg intravenously every 8 h
Number of subjects: 153

Group type: COMPARATOR
Intervention: Ceftazidime 2 g every 8 h + amikacin 15 mg/kg/day
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Meropenem 1 g every 8 h
Number of subjects: 153

Group type: COMPARATOR
Intervention: Ceftazidime + amikacin
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 153
Study: 2394323

Group type: EXPERIMENTAL
Intervention: Ramp distention with water
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ramp distention with air
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low infusion rates
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rapid intermittent distention
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ramp inflation at lower infusion rates
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All circumstances of rectal sensation
Number of subjects: 12
Study: 7436164

Group type: EXPERIMENTAL
Intervention: Activated oral charcoal, 6 g daily for 8 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo dextrose
Number of subjects: 11
Study: 31502859

Group type: EXPERIMENTAL
Intervention: Doravirine (MK‐1439)
Number of subjects: 0
Study: 27956164

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 136

Group type: COMPARATOR
Intervention: Endoscopic surveillance (control)
Number of subjects: 136
Study: 25600063

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 96

Group type: COMPARATOR
Intervention: Dorsal hand vein
Number of subjects: 96

Group type: COMPARATOR
Intervention: Saphenous vein
Number of subjects: 96
Study: 24924991

Group type: EXPERIMENTAL
Intervention: Augmented post-remission therapy (regimen C) including additional eight doses of pegylated asparaginase, 18 doses of vincristine, and escalated-dose intravenous methotrexate without folinic acid rescue.
Number of subjects: 533

Group type: COMPARATOR
Intervention: Standard therapy (treatment regimens A and B).
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Augmented post-remission therapy (regimen C).
Number of subjects: 533
Study: 22982948

Group type: EXPERIMENTAL
Intervention: Park environment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Urban environment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both environments
Number of subjects: 40
Study: 19916990

Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg once daily for 3 months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 17515510

Group type: EXPERIMENTAL
Intervention: Topical 0.4% retinol lotion
Number of subjects: 36

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 36
Study: 15477633

Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg once daily)
Number of subjects: 907

Group type: COMPARATOR
Intervention: Tamoxifen (20 mg once daily)
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 907

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 907
Study: 11472700

Group type: EXPERIMENTAL
Intervention: RPR 109891 (oral glycoprotein IIb/IIIa antagonist) plus aspirin
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: RPR 109891 (oral glycoprotein IIb/IIIa antagonist)
Number of subjects: 420
Study: 9551029

Group type: EXPERIMENTAL
Intervention: fluvastatin 60 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: fenofibrate (micronized) 200 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: simvastatin 20 mg/day
Number of subjects: 0
Study: 8064370

Group type: EXPERIMENTAL
Intervention: Diet A (12% of total energy as protein)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Diet B (21% of total energy as protein)
Number of subjects: 55
Study: 1776743

Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC)
Number of subjects: 0
Study: 673095

Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide suspension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aluminum carbonate powder in capsule form
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31383235

Group type: EXPERIMENTAL
Intervention: Montelukast and fluticasone (anti-inflammatory treatment) for 12 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 26
Study: 28498504

Group type: EXPERIMENTAL
Intervention: Varenicline (2 mg/day, after 1-week dose run-up)
Number of subjects: 137

Group type: COMPARATOR
Intervention: NRT (21 mg/day decreasing to 7 mg/day)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 137

Group type: COMPARATOR
Intervention: NRT
Number of subjects: 137
Study: 26342874

Group type: EXPERIMENTAL
Intervention: Porous organogel materials coupled with liquid chromatography-tandem mass spectrometry (LC-MS-MS) for BPA extraction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Porous organogel materials
Number of subjects: 0
Study: 22788525

Group type: EXPERIMENTAL
Intervention: Avanafil 50 mg
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Avanafil 100 mg
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Avanafil 200 mg
Number of subjects: 83

Group type: COMPARATOR
Intervention: Sildenafil 50 mg
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 20652250

Group type: EXPERIMENTAL
Intervention: A‐V Impulse (AVI) system
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (standard care with low molecular weight heparin)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 19249419

Group type: EXPERIMENTAL
Intervention: Nitrous oxide-containing anesthetic
Number of subjects: 7000

Group type: COMPARATOR
Intervention: Nitrous oxide-free anesthetic
Number of subjects: 7000
Study: 16453953

Group type: EXPERIMENTAL
Intervention: 3 component acellular pertussis vaccine (GlaxoSmithKline)
Number of subjects: 2781

Group type: COMPARATOR
Intervention: Hepatitis A vaccine (Havrix) as a placebo
Number of subjects: 2781
Study: 16194997

Group type: EXPERIMENTAL
Intervention: Mental arithmetic
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Mental arithmetic combined with exercise
Number of subjects: 62

Group type: COMPARATOR
Intervention: Competitive exercise
Number of subjects: 62

Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Exercise tasks
Number of subjects: 62
Study: 12958109

Group type: EXPERIMENTAL
Intervention: 20 mg oral morphine (sustained release)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 9917047

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate nasal spray, 100 microg/day for 4 to 6 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no steroid exposure)
Number of subjects: 21
Study: 7561986

Group type: EXPERIMENTAL
Intervention: Latex particle agglutination test (LPAT) for N. meningitidis C
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Latex particle agglutination test (LPAT) for H. influenzae type b
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Latex particle agglutination test (LPAT) for S. pneumoniae
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Latex particle agglutination test (LPAT) for all three organisms
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Positive predictive value for children < 5 years
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Posttest probability for children < 5 years
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Positive predictive value for children < 14 years
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Posttest probability for children < 14 years
Number of subjects: 299
Study: 2197376

Group type: EXPERIMENTAL
Intervention: Propranolol-LA, 80-mg tablets
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Atenolol, 50-mg tablets
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (no beta blocker therapy)
Number of subjects: 42
Study: 6995615

Group type: EXPERIMENTAL
Intervention: EMG biofeedback training
Number of subjects: 31

Group type: COMPARATOR
Intervention: Pseudotherapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Symptom-monitoring control group
Number of subjects: 31
Study: 12166539

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) 56 microg b.i.d.
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) 200 microg b.i.d.
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) 500 microg b.i.d.
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 168 microg b.i.d.
Number of subjects: 395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: All active treatments (MF and BDP)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Active treatments (MF and BDP)
Number of subjects: 395
Study: 29342865

Group type: EXPERIMENTAL
Intervention: Brown seaweed extract
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 27514714

Group type: EXPERIMENTAL
Intervention: Sleep intervention
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: FAB intervention
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: Combination intervention
Number of subjects: 802

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 802
Study: 24676204

Group type: EXPERIMENTAL
Intervention: Live Attenuated Influenza Vaccine (LAIV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inactivated Influenza Vaccine (IIV)
Number of subjects: 0
Study: 22341282

Group type: EXPERIMENTAL
Intervention: Web based interview process via Skype
Number of subjects: 39

Group type: COMPARATOR
Intervention: Traditional on‐site interview process
Number of subjects: 39
Study: 20332352

Group type: EXPERIMENTAL
Intervention: bromocriptine-QR
Number of subjects: 3095

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 3095
Study: 18606284

Group type: EXPERIMENTAL
Intervention: Deployment of six speed cameras along an 8-mile corridor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Speed cameras
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Public opinion surveys
Number of subjects: 0
Study: 16110283

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 12182275

Group type: EXPERIMENTAL
Intervention: Supportive-expressive group therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 10839650

Group type: EXPERIMENTAL
Intervention: Cyclic progesterone (EP)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Estrogen alone (ES)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 7502281

Group type: EXPERIMENTAL
Intervention: Antegrade cardioplegia
Number of subjects: 21

Group type: COMPARATOR
Intervention: Retrograde cardioplegia
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study: 2310576

Group type: EXPERIMENTAL
Intervention: 0.05% oxymetazoline
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 10% cocaine
Number of subjects: 42

Group type: COMPARATOR
Intervention: 4% lidocaine with 1:100,000 epinephrine
Number of subjects: 42
Study: 7002568

Group type: EXPERIMENTAL
Intervention: Verapamil 80-160 mg t.i.d. for 10 days
Number of subjects: 12
Study: 30477816

Group type: EXPERIMENTAL
Intervention: Intervention group (low-Cd rice)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Non-intervention group (high-Cd rice)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (low-Cd rice)
Number of subjects: 106
Study: 29197412

Group type: EXPERIMENTAL
Intervention: Reward group (n = 37) using performance feedback and contingent monetary reward
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (n = 37) using the same system but without monetary reward and with reduced performance feedback
Number of subjects: 74
Study: 25739726

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 46

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 46
Study: 23770377

Group type: COMPARATOR
Intervention: Almorexant 100mg in subjects with mild liver impairment (Group A)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Almorexant 100mg in subjects with moderate liver impairment (Group B)
Number of subjects: 35
Study: 21632265

Group type: EXPERIMENTAL
Intervention: Esmolol infusion
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study: 19220277

Group type: EXPERIMENTAL
Intervention: Microemulsion propofol
Number of subjects: 147

Group type: COMPARATOR
Intervention: Lipid emulsion propofol
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: 8% PEG660 HS
Number of subjects: 147
Study: 16699123

Group type: EXPERIMENTAL
Intervention: Standard Life Skills Training (LST)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infused Life Skills Training (LST) delivery method
Number of subjects: 0
Study: 14660159

Group type: EXPERIMENTAL
Intervention: Antiretroviral medication adherence on drug use days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Antiretroviral medication adherence on matched abstinence days
Number of subjects: 12
Study: 10719624

Group type: EXPERIMENTAL
Intervention: Spleen peptide preparation (Polyerga) during chemotherapy (cisplatin/carboplatin, 5‐fluorouracil)
Number of subjects: 40
Study: 8842556

Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone for 7 days
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 1847239

Group type: EXPERIMENTAL
Intervention: CT imaging
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: MR imaging
Number of subjects: 170
Study: 6884410

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Propranolol glucuronide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 4-hydroxypropranolol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 4-hydroxypropranolol glucuronide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Naphthoxylactic acid
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Propranolol binding in cord plasma
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Naphthoxylactic acid binding in cord plasma
Number of subjects: 10
Study: 31177631

Group type: EXPERIMENTAL
Intervention: M-SAKHI intervention delivered by ASHAs
Number of subjects: 2501

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2501

Group type: EXPERIMENTAL
Intervention: M-SAKHI intervention
Number of subjects: 2501
Study: 28338706

Group type: EXPERIMENTAL
Intervention: 24-h urine samples
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Spot urine samples using Tanaka equation
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Spot urine samples using Kawasaki equation
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Spot urine samples using Mage equation
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Spot urine samples using Toft equation
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Spot urine samples using INTERSALT equation
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Spot urine samples using INTERSALT equation with potassium
Number of subjects: 1000
Study: 26087958

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/rosuvastatin 10 mg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Rosuvastatin 20 mg
Number of subjects: 43
Study: 23548674

Group type: EXPERIMENTAL
Intervention: High-flux dialysis
Number of subjects: 618

Group type: COMPARATOR
Intervention: Low-flux dialysis
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Patients with cardiovascular disease and NT-proBNP above median
Number of subjects: 618
Study: 21817939

Group type: EXPERIMENTAL
Intervention: Bone‐Anchored Hearing Aid surgery without skin thinning (test group)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Traditional Bone‐Anchored Hearing Aid procedure (control group)
Number of subjects: 18
Study: 19466746

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 108
Study: 16682725

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (GCSF) added to prophylactic antibiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prophylactic antibiotics alone
Number of subjects: 0
Study: 15293487

Group type: EXPERIMENTAL
Intervention: Augmented physiotherapy input (double the amount of physiotherapy)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Normal physiotherapy input (control group)
Number of subjects: 70
Study: 11763010

Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9504788

Group type: EXPERIMENTAL
Intervention: Fibre optic phototherapy (Ohmeda Biliblanket device)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Conventional phototherapy
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Fibre optic phototherapy
Number of subjects: 124
Study: 8031229

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/d
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg/d
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg/d
Number of subjects: 355

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355
Study: 2574627

Group type: EXPERIMENTAL
Intervention: Terfenadine 240 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg
Number of subjects: 12
Study: 4906702

Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 32